European Drug Index PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download European Drug Index PDF full book. Access full book title European Drug Index by Niels F. Muller. Download full books in PDF and EPUB format.
Author: Niels F. Muller
Publisher: Routledge
ISBN: 1351449478
Category : Medical
Languages : en
Pages : 776
Get Book Here
Book Description
Many health care providers are frequently dealing with problems related to the identification and interpretation of medicines and prescriptions of foreign origin. Health authorities, customs and travel agencies also encounter such problems, which are related to the increasing mobility of the European population. Thus the need for a European Drug Index is obvious. The EDI provides extended information for practitioners confronted with the enormous number of drug names available on the European pharmaceutical market. This market is increasing due to the rapidly changing palette of countries and economic restrictions in Europe. The listings have been derived from drug data sources from the increased number of participating countries in this second edition. Each item starts with a trade name, in alphabetical order, followed by (depending on the original source) dosage forms, strength, volume (if applicable), and generic name(s) of the active principle(s) in a random sequence. The item is concluded by the Anatomical Therapeutic Chemical (ATC) classification (when made available by the original source) and a code for the country of origin.
Author: Niels F. Muller
Publisher: Routledge
ISBN: 1351449478
Category : Medical
Languages : en
Pages : 776
Get Book Here
Book Description
Many health care providers are frequently dealing with problems related to the identification and interpretation of medicines and prescriptions of foreign origin. Health authorities, customs and travel agencies also encounter such problems, which are related to the increasing mobility of the European population. Thus the need for a European Drug Index is obvious. The EDI provides extended information for practitioners confronted with the enormous number of drug names available on the European pharmaceutical market. This market is increasing due to the rapidly changing palette of countries and economic restrictions in Europe. The listings have been derived from drug data sources from the increased number of participating countries in this second edition. Each item starts with a trade name, in alphabetical order, followed by (depending on the original source) dosage forms, strength, volume (if applicable), and generic name(s) of the active principle(s) in a random sequence. The item is concluded by the Anatomical Therapeutic Chemical (ATC) classification (when made available by the original source) and a code for the country of origin.
Author: Muller
Publisher: CRC Press
ISBN: 3769221141
Category : Medical
Languages : en
Pages : 776
Get Book Here
Book Description
This fourth edition of the European Drug Index provides information about drugs available on the European market arranged alphabetically by trade name, including
Author: Bonnie Snow
Publisher: Scarecrow Press
ISBN: 9780810833210
Category : Health & Fitness
Languages : en
Pages : 772
Get Book Here
Book Description
Designed for use as a self-study text, as a course text in more formal instruction programs, or as a refresher for the busy professional, the book includes valuable background data on legal and regulatory issues, as well as pharmaceutical technology.
Author: Tim Boekhout van Solinge
Publisher: Boom Koninklijke Uitgevers
ISBN: 9789054545187
Category : Law
Languages : en
Pages : 268
Get Book Here
Book Description
Mind-altering drugs such as cannabis, cocaine, heroin and others are illegal in many parts of the world, but distinct approaches for dealing with the question of illegal drug use have been developed country by country. In this book Tim Boekhout van Solinge describes the different approaches that have been adopted to dealing with the problem, with particular reference to the experience of France, the Netherlands and Sweden. He explores the justifications and rationalizations for the divergent, often contradictory attitudes and systems that have been developed, and concludes that differing national cultural traditions for handling social problems have greatly influenced the ways in which illicit drug use have been dealt with.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Niels F. Muller
Publisher:
ISBN: 9789012064279
Category : Drugs
Languages : en
Pages : 819
Get Book Here
Book Description
Author: Mindy J. Allport-Settle
Publisher: Pharmalogika
ISBN: 9780982147603
Category : Law
Languages : en
Pages : 686
Get Book Here
Book Description
This title combines all of the human and veterinary Regulations, Directives and guidance for medicinal products used by the pharmaceutical industry as their main source when manufacturing and distributing medicinal products in the European Union.
Author: European Monitoring Centre for Drugs and Drug Addiction
Publisher:
ISBN: 9789291680139
Category : Drug abuse
Languages : en
Pages : 0
Get Book Here
Book Description
The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in the drugs field or indeed anyone seeking the latest findings on drugs in Europe. Published every autumn, the report contains non-confidential data supported by an extensive range of figures.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309212421
Category : Medical
Languages : en
Pages : 318
Get Book Here
Book Description
Medical devices that are deemed to have a moderate risk to patients generally cannot go on the market until they are cleared through the FDA 510(k) process. In recent years, individuals and organizations have expressed concern that the 510(k) process is neither making safe and effective devices available to patients nor promoting innovation in the medical-device industry. Several high-profile mass-media reports and consumer-protection groups have profiled recognized or potential problems with medical devices cleared through the 510(k) clearance process. The medical-device industry and some patients have asserted that the process has become too burdensome and is delaying or stalling the entry of important new medical devices to the market. At the request of the FDA, the Institute of Medicine (IOM) examined the 510(k) process. Medical Devices and the Public's Health examines the current 510(k) clearance process and whether it optimally protects patients and promotes innovation in support of public health. It also identifies legislative, regulatory, or administrative changes that will achieve the goals of the 510(k) clearance process. Medical Devices and the Public's Health recommends that the U.S. Food and Drug Administration gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices. According to the report, the FDA's finite resources are best invested in developing an integrated premarket and postmarket regulatory framework.
Author: Sean C. Sweetman
Publisher:
ISBN: 9780853697046
Category : Medical
Languages : en
Pages : 3335
Get Book Here
Book Description
This is thirty-fifth edition of Martindale, which provides reliable, and evaluated information on drugs and medicines used throughout the world. It contains encyclopaedic facts about drugs and medicines, with: 5,500 drug monographs; 128,000 preparations; 40,700 reference citations; 10,900 manufacturers. There are synopses of disease treatments which enables identification of medicines, the local equivalent and the manufacturer. It also Includes herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins, and poisons as well as drugs and medicines. Based on published information and extensively referenced
